GHRH Agonist MR-409 Enhances Macrophage-Induced Retinal Ganglion Cell Survival in Rats After Optic Nerve Injury
Background
Optic neuropathies like glaucoma are a primary cause of irreversible blindness, affecting over 100 million people globally through the progressive degeneration of retinal ganglion cells (RGCs). While previous research has shown that macrophage activation can increase RGC survival, the underlying signaling pathways are not fully understood. Conversely, antagonists of the growth hormone-releasing hormone (GHRH) have been shown to reduce endotoxin-induced inflammation by inhibiting macrophages. This study investigates the role of the GHRH receptor (GHRH-R) signaling pathway in neuroprotection, hypothesizing its involvement in inflammation-mediated RGC survival after injury.
Study Design
This study used an adult rat model of optic nerve injury induced by a crush procedure. The expression of the GHRH-R was first confirmed in the RGCs of the rat retina. Following the injury, rats were treated with subcutaneous applications of either the GHRH agonist MR-409 or the GHRH antagonist MIA-602. To assess the interaction with macrophage-mediated effects, some animals also received a lens injury or zymosan injection to induce macrophage activation. The primary endpoints were the survival of RGCs and changes in gene expression and protein phosphorylation in the retina.
Results
Both the GHRH agonist MR-409 and the antagonist MIA-602 promoted the survival of retinal ganglion cells (RGCs) after optic nerve crush. Both compounds also increased the phosphorylation of Akt in the retina, a key cell survival signaling protein. However, their effects on inflammation diverged significantly. Only the agonist MR-409 promoted microglia activation in the retina. In contrast, the antagonist MIA-602 significantly reduced the expression of inflammation-related genes Il1b, Il6, and Tnf.
Most importantly, the agonist MR-409 demonstrated an additive effect, further enhancing the RGC survival promoted by lens injury or zymosan-induced macrophage activation, whereas the antagonist MIA-602 attenuated this macrophage-driven protective effect. This highlights a crucial mechanistic difference in their neuroprotective actions.
Key Findings
- Both GHRH agonist MR-409 and antagonist MIA-602 promoted survival of retinal ganglion cells (RGCs) after optic nerve crush in rats.
- Only the GHRH agonist MR-409 promoted microglia activation in the retina.
- The GHRH antagonist MIA-602 significantly reduced the expression of inflammation-related genes Il1b, Il6, and Tnf.
- MR-409 additively enhanced RGC survival when combined with macrophage activation from lens injury or zymosan.
- MIA-602 attenuated the pro-survival effects of macrophage activation on RGCs.
Why It Matters
These findings suggest a novel therapeutic avenue for optic neuropathies like glaucoma. While both GHRH agonists and antagonists showed some neuroprotective effects, the agonist MR-409 uniquely synergized with the body's natural inflammatory response to enhance retinal cell survival. This implies that for conditions involving an inflammatory component, a GHRH agonist might be superior to an antagonist by working with, rather than against, certain aspects of the immune response. This research points toward the potential of GHRH agonists as a protective treatment for RGCs, especially when combined with therapies that modulate macrophage activity. However, these are preclinical results from a rat model, and significant further research is needed to determine safety, dosage, and efficacy in humans before any clinical application can be considered.
